Mengis Capital Management’s GSK GSK Stock Holding History

Mengis Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,766	Closed	-$762K	–	196
2024 Q1	$762K	Buy	+17,766	New	+$733K	0.12%	119

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Mengis Capital Management's GSK Position: Q2 2024 in Review

Mengis Capital Management sold out of GSK (GSK) in Q2 2024, closing a stake of 17,766 shares — an estimated $762K sold.

Mengis Capital Management first reported a position in GSK in Q1 2024 and held it in 1 quarter. The position peaked at $762K in Q1 2024. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

Mengis Capital Management reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
Mengis Capital Management sold 17,766 GSK shares in Q2 2024, an estimated $762K.
Mengis Capital Management first reported a position in GSK in Q1 2024 and held it in 1 quarter.
Mengis Capital Management's GSK position peaked at $762K in Q1 2024.
884 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Mengis Capital Management's 13F filing for Q2 2024, filed 17 Jul 2024.